Evidence map›Paper›PMID 22547991›Full record

ArticleTheScientificWorldJournal2012

Evaluation of clinical and immunopathological features of different infective doses of Trypanosoma cruzi in dogs during the acute phase.

Israel A Quijano-Hernández, Alejandro Castro-Barcena, Esteban Aparicio-Burgos, Marco A Barbosa-Mireles, Julio V Cruz-Chan, Juan C Vázquez-Chagoyán, Manuel E Bolio-González, Eric Dumonteil

Open access · goldAbstract read
In one paragraph

Article in TheScientificWorldJournal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Israel A Quijano-HernándezFacultad de Medicina Veterinaria y Zootecnia, Universidad Autónoma del Estado de México, Cerrillo Piedras Blancas s/n, 50200 Toluca, Mexico. iaquijanoh@uaemex.mx
Alejandro Castro-Barcena
Esteban Aparicio-Burgos
Marco A Barbosa-Mireles
Julio V Cruz-Chan
Juan C Vázquez-Chagoyán
Manuel E Bolio-González
Eric Dumonteil
Universidad Autónoma del Estado de México · MXAutonomous University of Yucatán · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infection with Trypanosoma cruzi is a major risk in Latin America, and dogs are believed to be good models for evaluating Chagas disease. Here, we evaluated the clinical and immunopathological alterations developed by mongrel dogs experimentally infected with different infective doses (2,000, 20,000, and 200,000 metacyclic trypomastigotes of Sylvio X10/4 strain kg(-1) via intraperitoneal). Clinical and electrocardiographic parameters, as well as antibody production and pathologic lesions were evaluated. All three doses of this strain of T. cruzi induced a similar pattern of infection characterized by cardiac arrhythmias and severe and diffuse myocarditis. Specific anti-T. cruzi IgG indicated seroconversion by day 14 after infection, and IgG levels increased during the period of evaluation. Mortality was observed only in dogs infected with the medium or high parasite doses, but not in the group infected with a low dose of 2,000 parasites kg(-1). Infection with a low dose of parasites provides an excellent nonlethal model to evaluate the immunopathology of the acute disease in dogs infected with the Sylvio X10/4 strain of T. cruzi.

Indexed as

AnimalsChagas DiseaseDog DiseasesDogsElectrocardiographyTrypanosoma cruzi

Identifiers

PMID22547991
PMCPMC3323355
OpenAlexW1977092868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.